Yamanaka Ryuya, Yajima Naoki, Abe Takashi, Tsuchiya Naoto, Homma Junpei, Narita Miwako, Takahashi Masuhiro, Tanaka Ryuichi
Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata City 951-8585, Japan.
Int J Oncol. 2003 Jul;23(1):5-15.
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. In this review, we will discuss the implications of these findings for glioma therapy. A literature review of dendritic cell-based glioma immunotherapy was used to overview the dendritic cell in immunobiology, in the central nervous system and in tumor immunology, glioma-associated antigens, dendritic cell therapy in animal glioma model, dendritic cell therapy in clinical trials and future directions in dendritic cell therapy. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Dendritic cell therapy of glioma seems to be safe and without major side effects. Its efficacy should be further determined in randomized, controlled clinical trials. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma.
尽管放射治疗、化学治疗以及手术切除技术有所进步，但恶性胶质瘤患者的预后仍然很差。在目前针对恶性胶质瘤研究的新治疗方法中，免疫疗法在理论上极具吸引力，因为它具有产生高度肿瘤特异性细胞毒性的潜力。越来越多的报告表明，使用树突状细胞的全身免疫疗法能够诱导抗胶质瘤反应。因此，基于树突状细胞的免疫疗法可能成为胶质瘤患者的一种新治疗方式。在本综述中，我们将讨论这些发现对胶质瘤治疗的意义。通过对基于树突状细胞的胶质瘤免疫疗法的文献回顾，概述了树突状细胞在免疫生物学、中枢神经系统和肿瘤免疫学中的作用、胶质瘤相关抗原、动物胶质瘤模型中的树突状细胞治疗、临床试验中的树突状细胞治疗以及树突状细胞治疗的未来方向。基于树突状细胞的免疫疗法策略作为一种成功诱导抗肿瘤免疫反应并提高胶质瘤患者生存率的方法，似乎很有前景。胶质瘤的树突状细胞治疗似乎是安全的，且没有严重的副作用。其疗效应在随机对照临床试验中进一步确定。为了疫苗接种目的而操纵树突状细胞的方法的发展将提高这些细胞在恶性胶质瘤生物治疗中的临床实用性。
